December 12, 2016 / 1:58 PM / a year ago

BRIEF-Cellectar Biosciences says USPTO grants patent for Paclitaxel PDC

Dec 12 (Reuters) - Cellectar Biosciences Inc

* Cellectar Biosciences announces USPTO grants patent for Paclitaxel PDC; provides additional patent protection for select solid tumors through 2035

* Cellectar Biosciences - plan to initiate a Phase II trial for CLR 131 in patients with relapsed or refractory multiple myeloma and select hematologic malignancies in early 2017 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below